Systemic Anaplastic Large Cell Lymphoma

• CLINICAL_TRIALS trial_result · 2026-04-08
  Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]

  Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL…

• CLINICAL_TRIALS trial_result · 2022-05-26
  Clinical Trial Update: Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma [Phase 4]

  This is a Phase 4 trial of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma. The study is completed and…

• CLINICAL_TRIALS trial_result · 2021-10-14
  Clinical Trial Update: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]

  Phase 1 study of oral PF-02341066 (crizotinib) as a tyrosine kinase inhibitor targeting c-Met/HGF pathway in advanced cancers; study complet…